Metformin Reduces NGF-Induced Tumour Promoter Effects in Epithelial Ovarian Cancer Cells
Author
dc.contributor.author
Garrido Palma, Maritza
Author
dc.contributor.author
Salvatierra, Renato
Author
dc.contributor.author
Valenzuela Valderrama, Manuel
Author
dc.contributor.author
Vallejos, Christopher
Author
dc.contributor.author
Bruneau, Nicole
Author
dc.contributor.author
Hernández, Andrea
Author
dc.contributor.author
Vega Blanco, María Margarita
Author
dc.contributor.author
Selman Abuchaibe, Alberto
Author
dc.contributor.author
Geoffery Quest, Andrew
Author
dc.contributor.author
Romero Osses, Carmen
Admission date
dc.date.accessioned
2021-04-09T17:23:11Z
Available date
dc.date.available
2021-04-09T17:23:11Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Pharmaceuticals 2020, 13, 315
es_ES
Identifier
dc.identifier.other
10.3390/ph13100315
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/179040
Abstract
dc.description.abstract
Epithelial ovarian cancer (EOC) is a lethal gynaecological neoplasm characterized by rapid growth and angiogenesis. Nerve growth factor (NGF) and its high affinity receptor tropomyosin receptor kinase A (TRKA) contribute to EOC progression by increasing the expression of c-MYC, survivin and vascular endothelial growth factor (VEGF) along with a decrease in microRNAs (miR) 23b and 145. We previously reported that metformin prevents NGF-induced proliferation and angiogenic potential of EOC cells. In this study, we sought to obtain a better understanding of the mechanism(s) by which metformin blocks these NGF-induced effects in EOC cells. Human ovarian surface epithelial (HOSE) and EOC (A2780/SKOV3) cells were stimulated with NGF and/or metformin to assess the expression of c-MYC, beta-catenin, survivin and VEGF and the abundance of the tumor suppressor miRs 23b and 145. Metformin decreased the NGF-induced transcriptional activity of MYC and beta-catenin/T-cell factor/lymphoid enhancer-binding factor (TCF-Lef), as well as the expression of c-MYC, survivin and VEGF in EOC cells, while it increased miR-23b and miR-145 levels. The preliminary analysis of ovarian biopsies from women users or non-users of metformin was consistent with these in vitro results. Our observations shed light on the mechanisms by which metformin may suppress tumour growth in EOC and suggest that metformin should be considered as a possible complementary therapy in EOC treatment.
es_ES
Patrocinador
dc.description.sponsorship
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDECYT
1160139
1130250
1170925
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDAP
15130011
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
21150360